Table 4.

Adjusted relative risks (95% confidence intervals) for first-line antiretroviral (ART) effectiveness at 12 and 24 months when assuming best-case (missing as success) and worst-case scenarios (missing as failure) (IPEC cohort, 2000 to 2010)

		12 months			24 months
		RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
		Missing excluded	Missing = Success	Missing = Failure	Missing excluded	Missing = Success	Missing = Failure
Age
	< 30				Ref.	Ref.	Ref.
	30-39				1.06 (0.94, 1.19)	1.01 (0.94, 1.09)	1.15 (0.99, 1.33)
	> = 40				1.12 (1.00, 1.26)	1.04 (0.97, 1.13)	1.24 (1.07, 1.44)
Gender/Risk category
	Women	0.90 (0.82, 0.99)	0.93 (0.87, 1.00)	0.87 (0.77, 0.98)	0.94 (0.84, 1.06)	0.94 (0.87, 1.02)	0.98 (0.84, 1.14)
	Heterosexual men	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
	MSM	1.02 (0.93, 1.12)	1.03 (0.96, 1.11)	0.98 (0.87, 1.10)	1.11 (0.98, 1.25)	1.08 (0.99, 1.17)	1.05 (0.90, 1.22)
	IDU/Other	1.02 (0.89, 1.16)	1.03 (0.94, 1.14)	0.89 (0.75, 1.05)	0.95 (0.79, 1.13)	0.97 (0.87, 1.09)	0.87 (0.70, 1.09)
Education
	< 4 years	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
	4-8 years	1.07 (0.96, 1.18)	1.05 (0.97, 1.13)	1.05 (0.93, 1.20)	1.13 (0.99, 1.29)	1.06 (0.98, 1.16)	1.18 (1.00, 1.39)
	> 8 years	1.13 (1.03, 1.24)	1.08 (1.01, 1.17)	1.16 (1.03, 1.30)	1.14 (1.00, 1.29)	1.07 (0.99, 1.16)	1.21 (1.03, 1.41)
Initial ART regimen
	PI-based				Ref.	Ref.	Ref.
	NNRTI-based				1.17 (1.05, 1.31)	1.09 (1.02, 1.17)	1.21 (1.05, 1.39)
Calendar year of ART initiation
	2005-2009	1.25 (1.15, 1.35)	1.14 (1.08, 1.22)	1.34 (1.21, 1.49)	1.14 (1.03, 1.27)	1.11 (1.03, 1.19)	1.08 (0.95, 1.23)
	2000-2004	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Started ART in clinical trial
	No	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
	Yes	1.08 (1.01, 1.16)	1.05 (0.99, 1.11)	1.10 (1.00, 1.21)	1.12 (1.02, 1.23)	1.04 (0.98, 1.11)	1.24 (1.10, 1.39)